The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | Activity of zidesamtinib for ROS1+ NSCLC in TKI-naïve and pre-treated patients
Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses how activity of zidesamtinib for ROS1-positive non-small cell lung cancer (NSCLC) compares in tyrosine kinase inhibitor (TKI)-naïve patients and those previously treated with a ROS1 TKI. Zidesamtinib showed good activity in both cohorts in the ARROS-1 (NCT05118789) trial, and was effective in pre-treated patients with acquired resistance mechanisms. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
